XOMA Royalty Corporation is a biotechnology royalty aggregator. The Companyâ€™s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Employees

Sector

Entertainment Production

More about the company

Market Cap	710M 631M 589M 537M 1.01B 68.27B 1.02B 7.13B 2.76B 34.9B 2.67B 2.61B 112B	P/E 2024	-15.9x	P/E 2025	18.3x
Enterprise Value	758M 674M 629M 573M 1.08B 72.91B 1.09B 7.61B 2.95B 37.27B 2.85B 2.79B 120B	EV / Sales 2024	11.4x	EV / Sales 2025	7.24x
Free-Float	98.68%	Yield 2024 *	-	Yield 2025	-

09-02	XOMA Royalty Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-14	Ligand Pharmaceuticals Incorporated completed the acquisition of XOMA Royalty Corporation from a group of shareholders.	CI
07-14	Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase	MT
07-14	XOMA Royalty Corp Announces Management Changes	CI
07-14	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P TMI Index	CI
07-14	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P Global BMI Index	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from NASDAQ Composite Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000 Value Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Value Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Growth Benchmark	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Value Benchmark Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Growth Benchmark Index	CI
07-12	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000E Value Benchmark	CI

04-30	HC Wainwright Downgrades XOMA Royalty to Neutral From Buy, Adjusts Price Target to $39 From $97	MT
11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
17/09/25	XOMA Royalty announces closing of tender offer for HilleVax	RE
17/04/25	Benchmark Initiates XOMA Royalty at Buy With $35 Price Target	MT
29/04/24	Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	MT

07-14	XOMA Royalty : Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	PU
07-14	XOMA Royalty Announces Closing of Its Acquisition by Ligand	AQ
06-12	XOMA Royalty : Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	PU
06-12	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	AQ
04-28	XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA	BU

28/10/23	Obseva: Organon rétrocède la licence pour Ebopiprant, paiement d'étape éteint
28/10/23	Obseva: Organon gibt Lizenz für Ebopiprant zurück - Meilensteinanspruch erlischt
15/03/23	Kuros: le déploiement commercial du Magnetos a creusé le déficit en 2022
24/02/23	Obseva réduit la voilure autour de ses actifs restants
19/12/22	Obseva: la demande de retrait de sursis concordataire est acceptée

XOMA Royalty Corporation Share Price NYSE

Stocks

XOMAP

US98419J3059

Entertainment Production

Valuation: XOMA Royalty Corporation

Chart: XOMA Royalty Corporation

Latest news: XOMA Royalty Corporation

Last Transcript: XOMA Royalty Corporation

Analysts' recommendations: XOMA Royalty Corporation

Press Releases: XOMA Royalty Corporation

News in other languages: XOMA Royalty Corporation

Quotes and Performance

Managers and Directors: XOMA Royalty Corporation

Copyright Management

Financials

Company Profile

Manager	Title	Age	Since
Owen Hughes CEO	Chief Executive Officer	51	31/12/2022
Jeffrey Trigilio DFI	Director of Finance/CFO	42	11/01/2026
Bradley Sitko CIO	Chief Investment Officer	45	02/01/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XOMA ROYALTY CORPORATION	+0.04%	+0.08%	-	-	710M
LIVE NATION ENTERTAINMENT, INC.	+1.15%	-1.23%	+7.96%	+103.51%	39.32B
UNIVERSAL MUSIC GROUP N.V.	+0.92%	-2.30%	-42.91%	-42.24%	29.06B
ROKU, INC.	+0.75%	-0.19%	+46.74%	+121.98%	22.62B
WARNER MUSIC GROUP CORP.	-0.87%	-1.20%	-20.79%	-13.53%	14.03B
TKO GROUP HOLDINGS, INC.	-0.26%	-3.88%	-11.03%	+107.81%	12.84B
BOLLORÉ SE	-0.27%	+2.22%	-24.35%	-25.84%	11.67B
PARAMOUNT SKYDANCE CORPORATION	+1.71%	-4.62%	-50.24%	-20.77%	10.66B
MADISON SQUARE GARDEN SPORTS CORP.	+1.94%	+1.02%	+75.74%	+134.22%	9.8B
TOHO CO., LTD.	-0.03%	-0.82%	-17.81%	+54.41%	8.26B
Average	+0.51%	-1.16%	-4.08%	+46.62%	17.58B
Weighted average by Cap.	+0.67%	-1.26%	-3.38%	+50.79%

	2024	2025
Net sales	28.49M 25.31M 23.62M 21.53M 40.61M 2.74B 40.99M 286M 111M 1.4B 107M 105M 4.49B	52.15M 46.33M 43.25M 39.42M 74.34M 5.01B 75.03M 523M 203M 2.56B 196M 192M 8.23B
Net income	-13.82M -12.28M -11.46M -10.45M -19.7M -1.33B -19.89M -139M -53.75M -679M -51.89M -50.76M -2.18B	31.71M 28.18M 26.3M 23.97M 45.21M 3.05B 45.63M 318M 123M 1.56B 119M 116M 5B
Net Debt	14.02M 12.45M 11.62M 10.59M 19.98M 1.35B 20.16M 141M 54.5M 689M 52.62M 51.48M 2.21B	48.26M 42.88M 40.02M 36.48M 68.8M 4.64B 69.44M 484M 188M 2.37B 181M 177M 7.61B